10-Q: Monopar Reports Q2 2025 Loss, Advances Pipeline

Monopar Therapeutics Inc. reported an increased net loss for Q2 2025, while advancing its ALXN1840 Wilson disease program towards an NDA filing and progressing its radiopharmaceutical pipeline.

Summary

• Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on Wilson disease and radiopharmaceuticals for oncology.
• The company reported a net loss of $2.45 million for the three months ended June 30, 2025, compared to $1.72 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $5.08 million, up from $3.36 million in the prior year period.
• Cash, cash equivalents, and investments totaled $53.3 million as of June 30, 2025, down from $60.29 million at December 31, 2024.
• Management estimates current funds will be sufficient to meet obligations at least through December 31, 2026.
• Research and development (R&D) expenses increased to $1.73 million for Q2 2025 (from $1.13 million in Q2 2024) and $3.37 million for H1 2025 (from $2.10 million in H1 2024).
• General and administrative (G&A) expenses rose to $1.50 million for Q2 2025 (from $0.66 million in Q2 2024) and $3.08 million for H1 2025 (from $1.42 million in H1 2024).
• Interest income significantly increased to $0.78 million for Q2 2025 (from $0.07 million in Q2 2024) and $1.38 million for H1 2025 (from $0.16 million in H1 2024) due to higher bank balances from Q4 2024 funding.
• The company's accumulated deficit reached approximately $80.9 million as of June 30, 2025, with no revenue generated since inception.
• A 1-for-5 reverse stock split became effective on August 12, 2024, to regain Nasdaq compliance.
• As of July 31, 2025, 6,169,961 shares of common stock were outstanding.
• The company acquired exclusive worldwide license for ALXN1840 for Wilson disease from Alexion in October 2024, despite Alexion terminating the program based on Phase 2 mechanistic trial results.
• Monopar is preparing to submit a New Drug Application (NDA) for ALXN1840 to the FDA in early 2026.
• The company is progressing its radiopharmaceutical programs: MNPR-101-Zr (Phase 1 imaging), MNPR-101-Lu (Phase 1a therapeutic), and MNPR-101-Ac (late preclinical).
• An Expanded Access Program (EAP) for MNPR-101-Zr and MNPR-101-Lu is now open for enrollment at EDNOC in Houston, Texas.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to increasing losses, a significant accumulated deficit, and the explicit need for future capital raises. While there is pipeline progress and a strong cash position for the near term, the underlying financial performance is deteriorating, and the ALXN1840 asset carries a notable risk given its prior termination by Alexion despite Phase 3 success.

Positives

• Current cash, cash equivalents, and investments of $53.3 million are projected to fund operations at least through December 31, 2026, providing near-term financial stability.
• The company successfully in-licensed ALXN1840, a late-stage investigational drug for Wilson disease, which had a pivotal Phase 3 trial meet its primary endpoint for copper mobilization.
• Positive early clinical data for MNPR-101-Zr validated its tumor-targeting ability, supporting the potential of the radiopharmaceutical platform.
• Two human clinical trials for the MNPR-101 radiopharmaceutical program (MNPR-101-Zr and MNPR-101-Lu) are active and enrolling patients.
• An Expanded Access Program (EAP) for MNPR-101-Zr and MNPR-101-Lu has been authorized by the FDA, providing a pathway for patients with serious conditions to access these investigational agents.
• Significant increase in interest income to $1.38 million for the six months ended June 30, 2025, reflecting effective management of cash reserves.
• The management team possesses extensive experience in drug development, regulatory approval, and commercialization, with a track record of successful asset sales and drug approvals.

Negatives

• Net loss significantly increased to $5.08 million for the six months ended June 30, 2025, compared to $3.36 million in the prior year period, indicating growing operational expenses without revenue.
• Alexion Pharmaceuticals, Inc. terminated the ALXN1840 program in Wilson disease based on Phase 2 mechanistic trial results (failure to demonstrate net-negative copper balance and reduce hepatic copper concentration) and regulatory discussions, despite a successful Phase 3 primary endpoint, introducing uncertainty for Monopar's NDA.
• The company has an accumulated deficit of approximately $80.9 million and has not generated any revenue since inception, highlighting a reliance on external funding.
• Research and development expenses increased by $1.28 million and general and administrative expenses increased by $1.67 million for the six months ended June 30, 2025, compared to the same period in 2024, reflecting rising operational costs.
• The company's ability to raise future funds on acceptable terms is uncertain, and failure to do so could delay, restructure, or cease operations.
• A 1-for-5 reverse stock split was conducted in August 2024 to regain Nasdaq listing compliance, often a sign of prior stock price underperformance.

Risks

• The company is a clinical-stage biopharmaceutical company with a history of financial losses and expects to continue incurring significant losses, potentially never achieving profitability.
• Ability to raise sufficient funds for continued clinical, regulatory, and commercial development, including future milestone payments, is uncertain.
• The regulatory approval process for ALXN1840 is lengthy, expensive, and uncertain, with potential requirements for additional studies that the company may not be able to fund or whose results may not meet regulatory significance.
• Reliance on qualified third parties for manufacturing, non-clinical studies, and clinical trials poses risks if these parties fail to meet contractual duties or deadlines.
• Radiopharmaceutical technology is relatively novel, which may lead to unpredictable challenges, including radioisotope availability, safety misconceptions, and low market uptake, potentially impacting funding.
• Geopolitical events (Russia-Ukraine war, Israel-Hamas war) and market variables (inflation, volatility) may increase costs for supplies, delay manufacturing, restrict radioisotope availability, and make financing more difficult.
• Significant competition from other biopharmaceutical companies and academic institutions, many with greater resources, could make product candidates obsolete or non-competitive.
• Termination of third-party licenses would adversely affect rights to essential compounds and technologies.
• Failure to obtain and preserve intellectual property rights could allow competitors to develop and market competing drugs.
• Loss of key management or scientific personnel, or inability to recruit qualified employees, could lead to program delays and increased costs.
• Uncertain future impacts of COVID-19 or other pandemics could negatively affect business, financial condition, and ability to raise capital.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it advances its ALXN1840 program towards an NDA filing, progresses its MNPR-101 radiopharmaceutical clinical trials, and invests in expanding its pipeline. Management anticipates that currently available funds will be sufficient to meet obligations at least through December 31, 2026, but acknowledges the need for substantial additional long-term funding through equity offerings, debt financings, strategic partnerships, or grants to support future development and potential commercialization efforts.

Management Comments

• We expect that our current funds will be sufficient at least through December 31, 2026, in order for us to: (1) assemble a regulatory package and file an NDA for the in-licensed ALXN1840 investigational drug candidate for Wilson disease; (2) continue to conduct and conclude our first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr; (3) continue to conduct our first-in-human therapeutic clinical trial of MNPR-101-Lu; (4) advance our preclinical MNPR-101-Ac program into the clinic; and (5) invest in internal R&D projects to expand our radiopharmaceutical pipeline.
• Our strategic goal is to acquire, develop, and commercialize innovative treatments for patients with unmet medical needs.
• We are preparing to submit an NDA to the FDA in early 2026 for ALXN1840.
• We are actively exploring opportunities to expand our radiopharmaceutical pipeline primarily through internal development efforts.
• Our management team has extensive experience in developing therapeutics and medical technologies through global regulatory approval and commercialization, which increases the probability of success in advancing our product candidates.

Industry Context

Monopar operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on rare diseases (Wilson disease) and oncology (radiopharmaceuticals). The in-licensing of ALXN1840, despite its prior termination by Alexion, reflects a strategy to acquire late-stage assets, a common approach for smaller biotechs to accelerate pipeline development. The focus on radiopharmaceuticals aligns with a growing trend in precision oncology, where targeted therapies and imaging agents are gaining traction. The company's reliance on external funding and its accumulated deficit are typical for clinical-stage biotechs that have not yet brought a product to market.

Comparison to Industry Standards

• Monopar's accumulated deficit of approximately $80.9 million and lack of revenue are common for clinical-stage biopharmaceutical companies, many of which never achieve profitability or commercialize products independently.
• The increase in R&D and G&A expenses is consistent with a company advancing multiple clinical programs, similar to peers like smaller oncology or rare disease biotechs (e.g., smaller cap companies in the 'XBI' or 'BBH' ETFs).
• The 1-for-5 reverse stock split to regain Nasdaq compliance is a negative indicator, often seen in companies struggling with stock price performance, contrasting with more stable, revenue-generating biopharma firms.
• The in-licensing of ALXN1840, a drug that had a Phase 3 success but was terminated by a larger partner (Alexion/AstraZeneca) due to mechanistic trial results, presents a unique risk-reward profile. While it offers a late-stage asset, it carries the inherent challenge of overcoming the previous partner's concerns, which is not a standard acquisition scenario.
• The development of radiopharmaceuticals (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) places Monopar in a niche but growing segment, competing with companies like Novartis (Lutathera, Pluvicto), Telix Pharmaceuticals, and RayzeBio (acquired by Bristol Myers Squibb), though Monopar is at a much earlier clinical stage and with significantly fewer resources.
• The company's cash runway through December 31, 2026, is reasonable for a clinical-stage biotech, but the explicit need for future capital raises is a standard challenge for companies without commercialized products, requiring continuous investor confidence.

Corporate Governance

Legal Proceedings

• The company may be subject to claims and assessments from time to time in the ordinary course of business, but no claims have been asserted to date.

Related Party Transactions

• As of June 30, 2025, Tactic Pharma, LLC, the company's initial investor, beneficially owned 13.4% of Monopar's common stock, with no transactions between them during the three and six months ended June 30, 2025.
• Chandler D. Robinson, CEO and Co-Founder, is a common stockholder, Managing Member of Tactic Pharma, and Board member, receiving market-based salary, stock-based compensation, and performance-based incentive bonus.

Stakeholder Impact

• **Shareholders:** Face continued dilution risk from future capital raises and stock-based compensation. The increasing net loss and accumulated deficit indicate ongoing unprofitability, which could negatively impact share price. The reverse stock split in 2024 was a negative signal for existing shareholders.
• **Employees:** Benefit from stock-based compensation, which increased significantly in H1 2025, providing incentives and retention. The company's continued operations and pipeline advancement provide job security.
• **Customers (future patients):** Potential benefit from the development of ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for advanced cancers, offering new treatment and imaging options.
• **Suppliers/Creditors:** The company's current cash position provides stability for meeting short-term obligations, but long-term reliance on external funding introduces some credit risk.
• **Regulatory Authorities:** The company is actively engaging with the FDA for ALXN1840 NDA submission and has received authorization for an Expanded Access Program for MNPR-101, indicating compliance and proactive engagement.

Next Steps

• Assemble a regulatory package and file a New Drug Application (NDA) for ALXN1840 for Wilson disease to the FDA in early 2026.
• Continue to conduct and conclude the first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr.
• Continue to conduct the first-in-human therapeutic clinical trial of MNPR-101-Lu.
• Advance the preclinical MNPR-101-Ac program into the clinic.
• Invest in internal R&D projects to expand the radiopharmaceutical pipeline.
• Identify and potentially invent or license novel targets and drug candidates complementing radiopharmaceutical and rare disease programs.
• Seek regulatory approvals for any current or future drug product candidates that successfully complete registration clinical trials.
• Establish or purchase services for sales, marketing, and distribution infrastructure for commercialization.
• Develop or contract for manufacturing/quality capabilities and a reliable supply chain.
• Add or contract for required operational, financial, and management information systems and specialized expert personnel.

Key Dates

Recommendation

Monopar Therapeutics is a clinical-stage biopharmaceutical company with a high-risk, high-reward profile. While the company has a solid cash runway through December 2026 and is advancing multiple clinical programs, including the in-licensed ALXN1840 (despite its prior termination by Alexion) and promising radiopharmaceuticals, it continues to incur significant losses and has no revenue. The increasing burn rate and explicit need for substantial future capital raises present considerable financial risk. The prior reverse stock split also signals past performance challenges. For a seasoned investor, the current stage warrants a 'hold' as the company navigates critical regulatory milestones (ALXN1840 NDA) and further clinical development. A 'buy' would be premature given the financial losses and regulatory uncertainties, while a 'sell' would overlook the potential upside of its pipeline assets if successful. Monitoring progress on ALXN1840's NDA and radiopharmaceutical trial data will be crucial for future re-evaluation.

Keywords

Biopharmaceutical, Clinical-stage, Wilson disease, ALXN1840, Radiopharmaceuticals, MNPR-101, Oncology, Drug development, SEC filing, 10-Q, Biotech, Rare disease, Cancer imaging, Therapeutic radioisotopes, NDA filing, Clinical trials